Articles
Starpharma close to first major revenues
Ansell has secured Australian certification for a line of condoms coated with Starpharma's (ASX:SPL) VivaGel, and aims to launch a line of products in the next few months. [ + ]
bioCSL distributing transfusion testing tech in ANZ
CSL subsidiary bioCSL (ASX:CSL) has commenced distribution of Immucor's blood-transfusion compatibility testing technology Capture in Australia and New Zealand. [ + ]
The secret to twisting light
Scientists from the Australian National University (ANU) have uncovered the secret to twisting light at will - the latest step in the development of photonics. Their research has been published in the journal Nature Communications. [ + ]
The debate on criminalising research fraud
The BMJ has featured an article in which two experts go head to head discussing the potential criminalisation of research fraud. [ + ]
Inexpensive assay detects fake malaria drugs
Chemists from Oregon State University (OSU) have created a simple, inexpensive assay which can tell whether or not one of the primary drugs being used to treat malaria is genuine. [ + ]
Imugene picks exclusive manufacturer for HER-Vaxx
Imugene (ASX:IMU) has selected Swiss-based virosome specialist Mymetics as the exclusive manufacturer for its HER-Vaxx cancer immunotherapy product. [ + ]
Prima picks up US patent for cancer treatment CVac
The US patent office has approved Prima BioMed's (ASX:PRR) application for a patent protecting autologous cancer treatment candidate CVac. [ + ]
New council of international biotech associations formed
An international confederation of biotechnology trade associations, with membership across six continents, has created the International Council of Biotechnology Associations (ICBA), with the expressed purpose of advocating for public policies that support the global growth of the innovative biotechnology industry. [ + ]
FDA approves StarPharma's VivaGel trial design
The US FDA has granted Starpharma (ASX:SPL) a Special Protocol Assessment for the design of two phase III trials of VivaGel for the prevention of recurrent bacterial vaginosis. [ + ]
Fusion research facility reaches for the stars
The Australian Plasma Fusion Research Facility (APFRF) has been officially launched at the Australian National University (ANU). The laboratory has been significantly upgraded thanks to a Commonwealth investment of $7.9 million from the National Collaborative Research Infrastructure Scheme (NCRIS) and associated programs. [ + ]
Rhinomed partners to promote Turbine device
Rhinomed (ASX:RNO) has announced a partnership to promote its fitness breathing device Turbine at Fitness First gyms and revealed that sales of the device hit $201K during the June quarter. [ + ]
The shrinking human genome
Researchers from the Spanish National Cancer Research Centre (CNIO) have updated the number of human genes - those that can generate proteins - to 19,000. This is 1700 fewer genes than described in the most recent annotation. [ + ]
QRxPharma chair, three directors step down
Four QRxPharma (ASX:QRX) board members, including chairman Dr Peter Farrell, have resigned hours before a board-spill vote called by a group of unhappy shareholders. [ + ]
Regeneus secures rights to cancer vaccine for humans
Regeneus (ASX:RGS) has picked up exclusive rights to an autologous therapeutic cancer vaccine for humans, after having already secured the exclusive licence for veterinary applications. [ + ]
The physical effects of magic mushrooms
Researchers have examined the brain effects of the psychedelic chemical in magic mushrooms, called 'psilocybin', revealing the physical changes the chemical makes to the brain. [ + ]
